CA2303132C - Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports - Google Patents

Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports Download PDF

Info

Publication number
CA2303132C
CA2303132C CA002303132A CA2303132A CA2303132C CA 2303132 C CA2303132 C CA 2303132C CA 002303132 A CA002303132 A CA 002303132A CA 2303132 A CA2303132 A CA 2303132A CA 2303132 C CA2303132 C CA 2303132C
Authority
CA
Canada
Prior art keywords
formulation
scopolamine
intranasal
upright
inverted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002303132A
Other languages
English (en)
Other versions
CA2303132A1 (fr
Inventor
Jorge C. De Meireles
Vincent D. Romeo
Ramneik Dua
Prafulla K. Chowhan
Charanjit R. Behl
Anthony P. Sileno
Raja G. Achari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of CA2303132A1 publication Critical patent/CA2303132A1/fr
Application granted granted Critical
Publication of CA2303132C publication Critical patent/CA2303132C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des formulations pharmaceutiques contenant de la scopolamine, et plus particulièrement des formulations de gel intranasal comprenant du bromhydrate de scopolamine dans un excipient pharmaceutiquement acceptable, de préférence un gel intranasal. Cette formulation a un pH égal ou inférieur à environ 4,0, de préférence égal ou inférieur à 3,5 et une concentration en sel inférieure à environ 200 mM, et la solution de gel contient du poly[alcool de vinyle] comme agent gélifiant. Ces formulations intranasales sont particulièrement utiles pour la prévention et/ou le traitement des nausées et/ou des vomissements associés par exemple au mal des transports.
CA002303132A 1997-09-11 1998-09-11 Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports Expired - Fee Related CA2303132C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5865197P 1997-09-11 1997-09-11
US60/058,651 1997-09-11
PCT/US1998/018953 WO1999012544A1 (fr) 1997-09-11 1998-09-11 Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports

Publications (2)

Publication Number Publication Date
CA2303132A1 CA2303132A1 (fr) 1999-03-18
CA2303132C true CA2303132C (fr) 2002-07-09

Family

ID=22018094

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002303132A Expired - Fee Related CA2303132C (fr) 1997-09-11 1998-09-11 Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports

Country Status (5)

Country Link
EP (1) EP1027049A4 (fr)
JP (1) JP2002516815A (fr)
AU (1) AU742878B2 (fr)
CA (1) CA2303132C (fr)
WO (1) WO1999012544A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001291159A1 (en) * 2000-09-20 2002-04-02 Shahinian Jr., Lee Self-preserved nasal, inhalable, and topical ophthalmic preparations and medications
JP5391691B2 (ja) 2006-03-31 2014-01-15 和光純薬工業株式会社 ピラゾール系シアニン色素
KR101444712B1 (ko) 2007-01-31 2014-09-26 와코 쥰야꾸 고교 가부시키가이샤 게놈 ｄｎａ 단편의 증폭 또는 결실의 검출방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164227B (it) * 1983-05-13 1987-04-08 Angeli Inst Spa Composizione farmaceutica atta alla somministrazione nasale di sali quaternari d'ammonio ed attivita' anticolinergica
US7765615B2 (en) * 2007-03-28 2010-08-03 Michael Robert Eastwood Chest protector in sports medicine

Also Published As

Publication number Publication date
EP1027049A1 (fr) 2000-08-16
JP2002516815A (ja) 2002-06-11
EP1027049A4 (fr) 2001-09-05
AU742878B2 (en) 2002-01-17
WO1999012544A1 (fr) 1999-03-18
AU9385098A (en) 1999-03-29
CA2303132A1 (fr) 1999-03-18

Similar Documents

Publication Publication Date Title
US8980290B2 (en) Transdermal compositions for anticholinergic agents
CA2373821C (fr) Compositions topiques d'apport de prostaglandine e1
US6166025A (en) Pharmaceutical compositions containing eletriptran hemisulphate and caffeine
CA2374877C (fr) Formulations pharmaceutiques et procedes comprenant de la morphine s'administrant par voie intra-nasale
AU698065B2 (en) Topical ketoconazole emulsions
US20080025920A1 (en) Methods of treating hot flashes with formulations for transdermal or transmucosal application
ES2324909T3 (es) Preparado con principio activo en forma de pelicula con mejora de la estabilidad quimica y procedimiento para su fabricacion.
KR101400359B1 (ko) 안정화된 프로스타글란딘 ｅ 조성물
JP2003518498A (ja) 点眼薬としてのケトチフェンの使用
KR960030948A (ko) 비강투여용 비무기 식염용액
EP0651993B1 (fr) Composition de base pour administration percutanee et composition de medicament derivee de celle-ci
CA2303132C (fr) Formulation intranasale contenant de la scopolamine et methode de traitement du mal des transports
US4923875A (en) Method for treatment of mast cell-mediated dermatologic disorders
WO1999012545A2 (fr) Medicaments contenant acyclovir
AU714913B2 (en) Intranasal formulations for promoting sleep and method of using the same
JPH1045599A (ja) 経皮的使用のためのアセチルサリチル酸含有アルコール性溶液、抗血栓治療のためのその利用及び薬剤
WO2009152369A1 (fr) Formulation pharmaceutique du kétorolac pour une administration intranasale
EP2340016A2 (fr) Formule topique de dihydrate propionate 3-(2,2,2-trimethylhydrazinium)
US5770618A (en) Method for increasing the solubility of clemastine and pharmaceutical compositions prepared therefrom
KR100389671B1 (ko) 염산 테르비나핀을 함유하는 항진균제 외용 약제 조성물
WO1999024042A2 (fr) Composition gelifiante anti-androgenique stable
JP2945140B2 (ja) 経皮投与吸収促進組成物及び経皮投与外用組成物
JPH09169642A (ja) テトラヒドロゾリン含有液剤
JP3050917B2 (ja) 経皮投与基剤組成物とその薬剤組成物
WO2002026232A1 (fr) Composition pharmaceutique pour l'administration transmucosale d'une association dihydroergotamine/metoclopramide

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed